Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01338545 · ClinicalTrials.gov registry record
An Observational Study of Dosage Patterns in Routine Clinical Practice in Patients With Rheumatoid Arthritis (ACT-LIFE)
A clinical trial, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- 400
- Enrollment target
NCT01338545 is a clinical trial that has completed, run by Hoffmann-La Roche. The registered enrollment target is 400 participants.
The verdict
NCT01338545 has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- 400 participants
- Enrollment target
Study Summary
This observational study will evaluate the dosage patterns, safety and efficacy of RoActemra/Actemra (tocilizumab) in clinical practice in patients with moderate to severe rheumatoid arthritis who have not responded or are intolerant to at least one disease-modifying antirheumatic drug (DMARD) or TNF inhibitor. Data will be collected from each patients for 12 months.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01338545
The ClinicalTrials.gov registry entry for NCT01338545 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01338545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01338545 about?
NCT01338545 is a clinical study titled "An Observational Study of Dosage Patterns in Routine Clinical Practice in Patients With Rheumatoid Arthritis (ACT-LIFE)". This observational study will evaluate the dosage patterns, safety and efficacy of RoActemra/Actemra (tocilizumab) in clinical practice in patients with moderate to severe rheumatoid arthritis who have not responded or are intolerant to at least one disease-modifying antirheumatic drug (DMARD) or TN...
What is the current status of trial NCT01338545?
This trial is currently completed. The enrollment target is 400 participants. The study started on 2010-07. Estimated completion is 2012-09.
Who is sponsoring clinical trial NCT01338545?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.